Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo.
Bruno
Raffaele
R
Sacchi
Paolo
P
Filice
Gaetano
G
D019380:Anti-HIV Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects*; D016049:Didanosine / Q000009:adverse effects*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D007371:Interferon-gamma / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects*
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D012254:Ribavirin; D007371:Interferon-gamma; D016049:Didanosine